Comparing Medicure (OTCMKTS:MCUJF) & Achieve Life Sciences (NASDAQ:ACHV)

Medicure (OTCMKTS:MCUJF) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and target prices for Medicure and Achieve Life Sciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medicure	0	0	0	0	0.00
Achieve Life Sciences	1	0	3	2	3.00

Achieve Life Sciences has a consensus target price of $14.67, suggesting a potential upside of 198.41%. Given Achieve Life Sciences’ stronger consensus rating and higher possible upside, analysts clearly believe Achieve Life Sciences is more favorable than Medicure.

Institutional & Insider Ownership

33.5% of Achieve Life Sciences shares are held by institutional investors. 12.9% of Medicure shares are held by insiders. Comparatively, 3.0% of Achieve Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Medicure has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 2.27, meaning that its share price is 127% more volatile than the S&P 500.

Profitability

This table compares Medicure and Achieve Life Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medicure	-21.65%	-44.34%	-26.22%
Achieve Life Sciences	N/A	-193.49%	-111.88%

Earnings and Valuation

This table compares Medicure and Achieve Life Sciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicure	$20.65 million	0.40	-$5.08 million	($0.47)	-1.70
Achieve Life Sciences	N/A	N/A	-$54.65 million	($1.12)	-4.39

Medicure has higher revenue and earnings than Achieve Life Sciences. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Medicure, indicating that it is currently the more affordable of the two stocks.

About Medicure

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.

About Achieve Life Sciences

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.